Multi-part substitution infusion fluids and matching anticoagulants
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsPeter C. Chang, Jean-Michel Lannoy
Life of this patent
Estimating the term…
Abstract
A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
Claims20
1-24. (canceled)
A two part system for extracorporeal blood treatment comprising:
- a first substitution infusion fluid comprising electrolytes;
- and
- a second aqueous substitution infusion fluid comprising calcium ions, magnesium ions, glucose, potassium ions and phosphate ions.
A two part aqueous substitution infusion fluid for an extracorporeal blood treatment comprising:
- a first substitution infusion fluid comprising electrolytes and phosphate;
- and
- a second aqueous substitution infusion fluid comprising calcium ions, magnesium ions, glucose and potassium ions.
A substitution infusion fluid for an extracorporeal blood treatment comprising:
- sodium ions, calcium ions, magnesium ions, potassium ions, glucose, phosphate ions and bicarbonate ions.
A two part system for extracorporeal blood treatment comprising:
- a first substitution infusion fluid comprising electrolytes;
- and
- a second aqueous substitution infusion fluid comprising potassium ions and phosphate ions.
Dependencies are inferred from the claim text.